The NCPE does not recommend reimbursement of Nintedanib (Ofev®) at the submitted price.
The NCPE do not recommend reimbursement of Idelalisib (Zydelig®)
The NCPE recommends reimbursement in certain sub-populations of patients with genotype 1 & 4.
The NCPE recommends reimbursement of pembrolizumb for the first line treatment of unresectable or advanced metastic melanoma.
The NCPE does not recommend the reimbursement of pembrolizumab for this indication at the submitted price.
Reimbursement not recommended at the submitted price.
Ponatinib (Iclusig®) is not considered cost effective for its indication as stated and therefore is not recommended for reimbursement.
The NCPE does not recommend reimbursement of Olaparib (Lynparza®)
The NCPE recommends reimbursement of sofosbuvir and ledipasvir (Harvoni®) for patients with genotype 1 and genotype 4 hepatitis C infection.
Following NCPE assessment of the company sumbission, reimbursement of Vedolizumab (Entyvio®) is not recommended at submitted price.